Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor activity in solid tumor models “Pre-clinical data generated to-date demonstrates that CRB-601 ...
CRB-601 is designed to block the activation of latent TGFβ in the tumor microenvironment Phase 1 clinical study set to commence H1 2024 Pre-clinical data presented demonstrates robust anti-tumor ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback